Selected research
Market Structure
Global Liver Diseases Therapeutics Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Liver Diseases Therapeutics Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Liver Diseases Therapeutics Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Liver Diseases Therapeutics Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Liver Diseases Therapeutics Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Liver Diseases Therapeutics Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Liver Diseases Therapeutics Drugs include Achillion Pharmaceuticals, Angion Biomedica, F. Hoffmann-La Roche, Gilead Sciences, LG Life Sciences, Phenex Pharmaceuticals, ProMetic Life Sciences, Raptor Pharmaceuticals and Verva Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Liver Diseases Therapeutics Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Liver Diseases Therapeutics Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Liver Diseases Therapeutics Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Liver Diseases Therapeutics Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.
Liver Diseases Therapeutics Drugs Segment by Company
Achillion Pharmaceuticals
Angion Biomedica
F. Hoffmann-La Roche
Gilead Sciences
LG Life Sciences
Phenex Pharmaceuticals
ProMetic Life Sciences
Raptor Pharmaceuticals
Verva Pharmaceuticals
AbbVie
Bayer
GlaxoSmithKline
Merck
Johnson & Johnson
Shenzhen Kangtai Biological Products
Liver Diseases Therapeutics Drugs Segment by Type
Oral Liver Diseases Therapeutics Drugs
Injection Liver Diseases Therapeutics Drugs
Liver Diseases Therapeutics Drugs Segment by Application
Hospitals
Clinics
Other
Liver Diseases Therapeutics Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Liver Diseases Therapeutics Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Liver Diseases Therapeutics Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Liver Diseases Therapeutics Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Liver Diseases Therapeutics Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Liver Diseases Therapeutics Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Liver Diseases Therapeutics Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Liver Diseases Therapeutics Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Oral Liver Diseases Therapeutics Drugs
- Injection Liver Diseases Therapeutics Drugs
Applications
- Hospitals
- Clinics
- Other
Companies covered
- Achillion Pharmaceuticals
- Angion Biomedica
- F. Hoffmann-La Roche
- Gilead Sciences
- LG Life Sciences
- Phenex Pharmaceuticals
- ProMetic Life Sciences
- Raptor Pharmaceuticals
- Verva Pharmaceuticals
- AbbVie
- Bayer
- GlaxoSmithKline
- Merck
- Johnson & Johnson
- Shenzhen Kangtai Biological Products
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Liver Diseases Therapeutics Drugs Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Liver Diseases Therapeutics Drugs Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Liver Diseases Therapeutics Drugs Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Liver Diseases Therapeutics Drugs Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Liver Diseases Therapeutics Drugs Market Dynamics
- 2.1 Liver Diseases Therapeutics Drugs Industry Trends
- 2.2 Liver Diseases Therapeutics Drugs Industry Drivers
- 2.3 Liver Diseases Therapeutics Drugs Industry Opportunities and Challenges
- 2.4 Liver Diseases Therapeutics Drugs Industry Restraints
3 Liver Diseases Therapeutics Drugs Market by Manufacturers
- 3.1 Global Liver Diseases Therapeutics Drugs Revenue by Manufacturers (2021-2026)
- 3.2 Global Liver Diseases Therapeutics Drugs Sales by Manufacturers (2021-2026)
- 3.3 Global Liver Diseases Therapeutics Drugs Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Liver Diseases Therapeutics Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Liver Diseases Therapeutics Drugs Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Liver Diseases Therapeutics Drugs Manufacturers, Product Type & Application
- 3.7 Global Liver Diseases Therapeutics Drugs Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Liver Diseases Therapeutics Drugs Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Liver Diseases Therapeutics Drugs Players Market Share by Revenue in 2025
- 3.8.3 2025 Liver Diseases Therapeutics Drugs Tier 1, Tier 2, and Tier 3
4 Liver Diseases Therapeutics Drugs Market by Type
- 4.1 Liver Diseases Therapeutics Drugs Type Introduction
- 4.1.1 Oral Liver Diseases Therapeutics Drugs
- 4.1.2 Injection Liver Diseases Therapeutics Drugs
- 4.2 Global Liver Diseases Therapeutics Drugs Sales by Type
- 4.2.1 Global Liver Diseases Therapeutics Drugs Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Liver Diseases Therapeutics Drugs Sales by Type (2021-2032)
- 4.2.3 Global Liver Diseases Therapeutics Drugs Sales Market Share by Type (2021-2032)
- 4.3 Global Liver Diseases Therapeutics Drugs Revenue by Type
- 4.3.1 Global Liver Diseases Therapeutics Drugs Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Liver Diseases Therapeutics Drugs Revenue by Type (2021-2032)
- 4.3.3 Global Liver Diseases Therapeutics Drugs Revenue Market Share by Type (2021-2032)
5 Liver Diseases Therapeutics Drugs Market by Application
- 5.1 Liver Diseases Therapeutics Drugs Application Introduction
- 5.1.1 Hospitals
- 5.1.2 Clinics
- 5.1.3 Other
- 5.2 Global Liver Diseases Therapeutics Drugs Sales by Application
- 5.2.1 Global Liver Diseases Therapeutics Drugs Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Liver Diseases Therapeutics Drugs Sales by Application (2021-2032)
- 5.2.3 Global Liver Diseases Therapeutics Drugs Sales Market Share by Application (2021-2032)
- 5.3 Global Liver Diseases Therapeutics Drugs Revenue by Application
- 5.3.1 Global Liver Diseases Therapeutics Drugs Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Liver Diseases Therapeutics Drugs Revenue by Application (2021-2032)
- 5.3.3 Global Liver Diseases Therapeutics Drugs Revenue Market Share by Application (2021-2032)
6 Global Liver Diseases Therapeutics Drugs Sales by Region
- 6.1 Global Liver Diseases Therapeutics Drugs Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Liver Diseases Therapeutics Drugs Sales by Region (2021-2032)
- 6.2.1 Global Liver Diseases Therapeutics Drugs Sales by Region (2021-2026)
- 6.2.2 Global Liver Diseases Therapeutics Drugs Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Liver Diseases Therapeutics Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Liver Diseases Therapeutics Drugs Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Liver Diseases Therapeutics Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Liver Diseases Therapeutics Drugs Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Liver Diseases Therapeutics Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Liver Diseases Therapeutics Drugs Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Liver Diseases Therapeutics Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Liver Diseases Therapeutics Drugs Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Liver Diseases Therapeutics Drugs Revenue by Region
- 7.1 Global Liver Diseases Therapeutics Drugs Revenue by Region
- 7.1.1 Global Liver Diseases Therapeutics Drugs Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Liver Diseases Therapeutics Drugs Revenue by Region (2021-2026)
- 7.1.3 Global Liver Diseases Therapeutics Drugs Revenue by Region (2027-2032)
- 7.1.4 Global Liver Diseases Therapeutics Drugs Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Liver Diseases Therapeutics Drugs Revenue (2021-2032)
- 7.2.2 North America Liver Diseases Therapeutics Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Liver Diseases Therapeutics Drugs Revenue (2021-2032)
- 7.3.2 Europe Liver Diseases Therapeutics Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Liver Diseases Therapeutics Drugs Revenue (2021-2032)
- 7.4.2 Asia-Pacific Liver Diseases Therapeutics Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Liver Diseases Therapeutics Drugs Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Liver Diseases Therapeutics Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Achillion Pharmaceuticals
- 8.1.1 Achillion Pharmaceuticals Company Information
- 8.1.2 Achillion Pharmaceuticals Business Overview
- 8.1.3 Achillion Pharmaceuticals Liver Diseases Therapeutics Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Achillion Pharmaceuticals Liver Diseases Therapeutics Drugs Product Portfolio
- 8.1.5 Achillion Pharmaceuticals Recent Developments
- 8.2 Angion Biomedica
- 8.2.1 Angion Biomedica Company Information
- 8.2.2 Angion Biomedica Business Overview
- 8.2.3 Angion Biomedica Liver Diseases Therapeutics Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Angion Biomedica Liver Diseases Therapeutics Drugs Product Portfolio
- 8.2.5 Angion Biomedica Recent Developments
- 8.3 F. Hoffmann-La Roche
- 8.3.1 F. Hoffmann-La Roche Company Information
- 8.3.2 F. Hoffmann-La Roche Business Overview
- 8.3.3 F. Hoffmann-La Roche Liver Diseases Therapeutics Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 F. Hoffmann-La Roche Liver Diseases Therapeutics Drugs Product Portfolio
- 8.3.5 F. Hoffmann-La Roche Recent Developments
- 8.4 Gilead Sciences
- 8.4.1 Gilead Sciences Company Information
- 8.4.2 Gilead Sciences Business Overview
- 8.4.3 Gilead Sciences Liver Diseases Therapeutics Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Gilead Sciences Liver Diseases Therapeutics Drugs Product Portfolio
- 8.4.5 Gilead Sciences Recent Developments
- 8.5 LG Life Sciences
- 8.5.1 LG Life Sciences Company Information
- 8.5.2 LG Life Sciences Business Overview
- 8.5.3 LG Life Sciences Liver Diseases Therapeutics Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 LG Life Sciences Liver Diseases Therapeutics Drugs Product Portfolio
- 8.5.5 LG Life Sciences Recent Developments
- 8.6 Phenex Pharmaceuticals
- 8.6.1 Phenex Pharmaceuticals Company Information
- 8.6.2 Phenex Pharmaceuticals Business Overview
- 8.6.3 Phenex Pharmaceuticals Liver Diseases Therapeutics Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Phenex Pharmaceuticals Liver Diseases Therapeutics Drugs Product Portfolio
- 8.6.5 Phenex Pharmaceuticals Recent Developments
- 8.7 ProMetic Life Sciences
- 8.7.1 ProMetic Life Sciences Company Information
- 8.7.2 ProMetic Life Sciences Business Overview
- 8.7.3 ProMetic Life Sciences Liver Diseases Therapeutics Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 ProMetic Life Sciences Liver Diseases Therapeutics Drugs Product Portfolio
- 8.7.5 ProMetic Life Sciences Recent Developments
- 8.8 Raptor Pharmaceuticals
- 8.8.1 Raptor Pharmaceuticals Company Information
- 8.8.2 Raptor Pharmaceuticals Business Overview
- 8.8.3 Raptor Pharmaceuticals Liver Diseases Therapeutics Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Raptor Pharmaceuticals Liver Diseases Therapeutics Drugs Product Portfolio
- 8.8.5 Raptor Pharmaceuticals Recent Developments
- 8.9 Verva Pharmaceuticals
- 8.9.1 Verva Pharmaceuticals Company Information
- 8.9.2 Verva Pharmaceuticals Business Overview
- 8.9.3 Verva Pharmaceuticals Liver Diseases Therapeutics Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 Verva Pharmaceuticals Liver Diseases Therapeutics Drugs Product Portfolio
- 8.9.5 Verva Pharmaceuticals Recent Developments
- 8.10 AbbVie
- 8.10.1 AbbVie Company Information
- 8.10.2 AbbVie Business Overview
- 8.10.3 AbbVie Liver Diseases Therapeutics Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.10.4 AbbVie Liver Diseases Therapeutics Drugs Product Portfolio
- 8.10.5 AbbVie Recent Developments
- 8.11 Bayer
- 8.11.1 Bayer Company Information
- 8.11.2 Bayer Business Overview
- 8.11.3 Bayer Liver Diseases Therapeutics Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.11.4 Bayer Liver Diseases Therapeutics Drugs Product Portfolio
- 8.11.5 Bayer Recent Developments
- 8.12 GlaxoSmithKline
- 8.12.1 GlaxoSmithKline Company Information
- 8.12.2 GlaxoSmithKline Business Overview
- 8.12.3 GlaxoSmithKline Liver Diseases Therapeutics Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.12.4 GlaxoSmithKline Liver Diseases Therapeutics Drugs Product Portfolio
- 8.12.5 GlaxoSmithKline Recent Developments
- 8.13 Merck
- 8.13.1 Merck Company Information
- 8.13.2 Merck Business Overview
- 8.13.3 Merck Liver Diseases Therapeutics Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.13.4 Merck Liver Diseases Therapeutics Drugs Product Portfolio
- 8.13.5 Merck Recent Developments
- 8.14 Johnson & Johnson
- 8.14.1 Johnson & Johnson Company Information
- 8.14.2 Johnson & Johnson Business Overview
- 8.14.3 Johnson & Johnson Liver Diseases Therapeutics Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.14.4 Johnson & Johnson Liver Diseases Therapeutics Drugs Product Portfolio
- 8.14.5 Johnson & Johnson Recent Developments
- 8.15 Shenzhen Kangtai Biological Products
- 8.15.1 Shenzhen Kangtai Biological Products Company Information
- 8.15.2 Shenzhen Kangtai Biological Products Business Overview
- 8.15.3 Shenzhen Kangtai Biological Products Liver Diseases Therapeutics Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.15.4 Shenzhen Kangtai Biological Products Liver Diseases Therapeutics Drugs Product Portfolio
- 8.15.5 Shenzhen Kangtai Biological Products Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Liver Diseases Therapeutics Drugs Value Chain Analysis
- 9.1.1 Liver Diseases Therapeutics Drugs Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Liver Diseases Therapeutics Drugs Production Mode & Process
- 9.2 Liver Diseases Therapeutics Drugs Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Liver Diseases Therapeutics Drugs Distributors
- 9.2.3 Liver Diseases Therapeutics Drugs Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst